Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
BMC Rheumatol. 2024 Feb 4;8(1):6 doi: 10.1186/s41927-024-00375-w
Increasing proportions of guselkumab-randomized patients met MDA domain criteria through
Week 100.
Higher baseline patients pain score, greater BMI, older age, and worse fatigue were significant determinants of longer time to achieve minimal patient pain. They were also indicative of a lower probability of achieving minimal patient pain at Week 100.
Keywords:
